TAO Synergies
TAOX | NASDAQ
$1.86
-$0.24 (-11.43%)
At close: Nov 16, 2026, 4:00 PM ET
$1.90
+$0.04 (+2.15%)
After-hours:
Nov 16, 2026, 5:23 PM ET
TAO Synergies Company Profile
Company profile explainedCompany Profile
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
Key Executives
| Name | Position |
|---|---|
| Robert Weinstein | Chief Financial Officer, Executive Vice President, Treasurer & Secretary |
| Alan J. Tuchman | Chief Medical Officer |
| Joshua N. Silverman | Executive Chairman of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | S-3/A | [Amend] Filing |
| Oct 09, 2026 | S-3/A | [Amend] Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Jun 05, 2026 | 10-K/A | [Amend] Annual Report |
| May 19, 2026 | 4 | Filing |
| May 19, 2026 | 4 | Filing |
| May 19, 2026 | 4 | Filing |
| May 19, 2026 | 4 | Filing |
| May 19, 2026 | 4 | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
TAO Synergies
| Country | United States |
| IPO Date | Jul 2, 2025 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 5 |
| CEO | Joshua N. Silverman |
Contact Details
1185 Avenue of the Americas, 3rd Floor New York,
New York 10036 United States
Stock Details
| Ticker Symbol | TAOX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001571934 |
| CUSIP Number | 87167T300 |
| ISIN Number | US87167T3005 |
| SIC Code | 6199 |
Add to Watchlist
Select watchlists to add or remove TAOX